Stability   Indicating   RP -HPLC   Method   Development   and   validation   for   the simultaneous  estimation  of  Ertugliflozin  and  Sitagliptin  in  Bulk  and  Pharmaceutical Dosage form

Rajareddy, Aleti; Divya, A

doi:10.54037/wjps.2021.91102

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To treat type 2 diabetes, ertugliflozin and sitagliptin were administered in a combined dosage form. There have been a few reported validated analytical techniques for estimating ertugliflozin and sitagliptin by RP-HPLC method (China et al, 2019;Rajeswari et al, 2022;Venkateswara et al, 2018;Raju et al, 2021;Vilas et al, 2022). It was found that no economically validated method was available from the literature for simultaneous estimation of Ertugliflozin and sitagliptin in bulk and tablet dosage form.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk drug and tablet dosage form

Mankar,

Sagar,

Bhawar

et al. 2023

IJERR

View full text Add to dashboard Cite

To treat type 2 diabetes, in a combined tablet dosage form the ertugliflozin and sitagliptin were administered. Considering the less complication and readily availability of HPLC, the main objective of present study was to develop a new, precise, accurate, linear, robust, and economical RP-HPLC method for the simultaneous estimation of ertugliflozin and sitagliptin in tablet dosage form. Effective chromatographic separation of Ertugliflozin and Sitagliptin was achieved on Kromasil C18 (5 µm 250 mm X 4.6 mm) and the mobile phase containing Methanol and 0.1% OPA in water isocratic elution mode at a flow rate of 1.0mL/min. with column temperature at 30 °C and the injection volume was 20 µL at column temperature at 30°C. At an isosbestic wavelength of 212 nm, ertugliflozin and sitagliptin were found to have retention times of 5.30 min. and 2.05 min., respectively. The method was proven to be precise (%RSD 2%), accurate (>90%), and specific for the simultaneous measurement of both drugs in tablets. As a result, the suggested method with excellent specificity, accuracy, precision, linearity and robustness as well as economical was useful for the regular quality control analysis of ertugliflozin and sitagliptin tablets.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and validation of RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk drug and tablet dosage form

Mankar,

Sagar,

Bhawar

et al. 2023

IJERR

View full text Add to dashboard Cite

show abstract

An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form

M. Sagar,

Mankar,

Dighe

2023

AJPA

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic condition characterized by hyperglycemia, glycosuria, hyperglycemia, a negative nitrogen balance, and occasionally ketonemia. The type 2 sodium-dependent glucose co-transporters (SGLT), which are in charge of roughly 90% of the reabsorption of glucose from the glomerulus, are subject to strong and selective inhibition by ertugliflozin. This review's primary objective is to highlight the development and validation of analytical methods employing chromatographic and spectrophotometric techniques for ertugliflozin and combination products in bulk and pharmaceutical dose forms. RP-HPLC, UV, UPLC, and LC-MS techniques are used to determine the dosage of ertugliflozin when it is combined with metformin and sitagliptin. Spectrometric techniques for ertugliflozin in combination with metformin or sitagliptin contain parameters like solvent, wavelength, linearity, LOD, LOQ, etc., and HPLC methods for ertugliflozin in combination with metformin or sitagliptin include parameters like stationary phase, mobile phase, RT, detection wavelength, LOD, LOQ, etc. Discussions on the separation requirements for ertugliflozin in combination with metformin or sitagliptin are also addressed throughout this review.

show abstract

Stability Indicating RP -HPLC Method Development and validation for the simultaneous estimation of Ertugliflozin and Sitagliptin in Bulk and Pharmaceutical Dosage form

Cited by 2 publications

References 0 publications

Development and validation of RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk drug and tablet dosage form

Development and validation of RP-HPLC method for simultaneous estimation of Ertugliflozin and Sitagliptin in bulk drug and tablet dosage form

An Overview on Analytical Method Development and Validation for Ertugliflozin in Bulk and Pharmaceutical Dosage form

Contact Info

Product

Resources

About